Investigators at Vanderbilt-Ingram Cancer Center and several other centers may be one step closer to finding out why some melanoma patients relapse after treatment with a promising new drug. Approximately half of all patients with the most deadly form of skin cancer have a mutation in the BRAF gene in their tumors that drives the […]
News: jeff sosman
Cousins with melanoma caused by the same genetic mutation enroll in a randomized clinical trial of a promising experimental drug that targets the mutation. Randomly assigned to different groups, one young man gets the new drug, experiences dramatic shrinkage of his tumors and is alive nine months later, while his cousin receives current therapy — […]
Patients with metastatic melanoma being treated with the new investigational cancer drug PLX4032 are showing strong responses, with an 80 percent anti-tumor response rate among patients whose tumors are positive for the B-RAF (V600E) gene mutation. However, in all too many cases, patients are developing resistance to the drug and their cancer is beginning to […]
A new drug used to treat advanced melanoma patients with a specific genetic mutation in their tumors demonstrated significant tumor shrinkage in the majority of patients during a clinical trials.
The Melanoma Research Alliance has awarded a three-year, $2 million grant to a multi-center team of cancer researchers investigating resistance to a new family of BRAF-targeted kinase inhibitor drugs. These targeted therapies are being tested in melanoma patients whose tumors carry a specific genetic mutation known as V600E BRAF. Jeff Sosman, M.D., professor of Medicine […]
A new documentary about the exciting era of personalized medicine and health care is now available on YouTube. Your Genome and the Future of Medicine, developed by Vanderbilt University Medical Center, initially aired on local stations in Lexington, Ky., and Nashville, Tenn. The 30-minute documentary, available for viewing in four segments, features interviews with several […]